We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Amarin Pharma, FDA Talk Settlement Of Off-Label Lawsuit After Injunction

(August 31, 2015, 12:45 PM EDT) -- NEW YORK — Amarin Pharma Inc. and the Food and Drug Administration are exploring the possibility of settling Amarin’s off-label speech lawsuit, counsel for the drug company told a New York federal judge on Aug. 28 (Amarin Pharma, Inc., v. United States Food & Drug Administration, et al., No. 15-3588, S.D. N.Y.).

(Letter available. Document #28-150903-019X.)

In a letter to U.S. Judge Paul A. Engelmayer of the Southern District of New York, Floyd Abrams of Cahill, Gordon & Reindel in New York says that pursuant to...
To view the full article, register now.